|
gptkbp:instance_of
|
gptkb:Cell
|
|
gptkbp:are_derived_from
|
a patient with non-Hodgkin lymphoma
|
|
gptkbp:can_be_engineered_to_express
|
chimeric antigen receptors (CARs)
|
|
gptkbp:can_be_expanded_in
|
gptkb:culture
|
|
gptkbp:can_be_frozen_and_stored_in
|
liquid nitrogen
|
|
gptkbp:can_be_genetically_modified_by
|
transfection
|
|
gptkbp:can_be_used_in
|
adoptive cell transfer therapy
|
|
gptkbp:can_be_used_to_target
|
HLA-negative tumors
|
|
gptkbp:can_create
|
cytokines
CD25
NKG2 D receptor
|
|
gptkbp:characterized_by
|
lack of T-cell markers
CD16 expression
CD56 expression
|
|
gptkbp:developed_by
|
gptkb:Yoshihiro_Takeda
|
|
gptkbp:exhibits
|
cytotoxicity
|
|
gptkbp:has_culture
|
RPMI-1640 medium
|
|
gptkbp:have_a_doubling_time_of
|
24 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NK-92 cells
|
|
gptkbp:initiated_by
|
IL-12
|
|
gptkbp:is_studied_for
|
natural killer cell biology
|
|
gptkbp:is_used_in
|
clinical trials
|
|
gptkbp:origin
|
gptkb:Human
|
|
gptkbp:requires
|
IL-2 for growth
|
|
gptkbp:sensitivity
|
certain chemotherapeutic agents
|
|
gptkbp:show_activity_against
|
tumor cells
|
|
gptkbp:type
|
natural killer cell
|
|
gptkbp:used_in
|
cancer immunotherapy
|
|
gptkbp:bfsParent
|
gptkb:Nant_Kwest
|
|
gptkbp:bfsLayer
|
5
|